SCTB14
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 24, 2026
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
(clinicaltrials.gov)
- P3 | N=246 | Recruiting | Sponsor: Sinocelltech Ltd.
IO biomarker • New P3 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1
March 12, 2024
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
(clinicaltrials.gov)
- P1/2 | N=515 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
Metastases • New P1/2 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1